A Review of the Rational and Current Evidence on Colchicine for COVID-19

被引:3
|
作者
Ghaith, Hazem S. [1 ]
Gabra, Mohamed Diaa [2 ]
Nafady, Mohamed H. [3 ]
Elshawah, Hamza Emad [4 ]
Negida, Ahmed [5 ,6 ]
Mushtaq, Gohar [7 ]
Kamal, Mohammad Amjad [8 ,9 ,10 ,11 ]
机构
[1] Al Azhar Univ, Fac Med, Cairo, Egypt
[2] South Valley Univ, Fac Med, Qena, Egypt
[3] Misr Univ Sci & Technol, Fac Appl Med Sci, 6th October City, Egypt
[4] Al Azhar Univ, Fac Med, New Damietta, Egypt
[5] Zagazig Univ, Fac Med, Zagazig, Egypt
[6] Univ Portsmouth, Sch Pharm & Biomed Sci, Portsmouth, England
[7] Idlib Univ, Fac Med, Ctr Sci Res, Idlib, Syria
[8] Sichuan Univ, West China Hosp, Inst Syst Genet, Frontiers Sci Ctr Dis Related Mol Network, Chengdu, Peoples R China
[9] King Abdulaziz Univ, King Fahd Med Res Ctr, Jeddah 21589, Saudi Arabia
[10] Daffodil Int Univ, Fac Allied Hlth Sci, Dept Pharm, Dhaka 1207, Bangladesh
[11] Enzymoics, Novel Global Community Educ Fdn, 7 Peterlee Pl, Hebersham, NSW 2770, Australia
关键词
Anti-inflammatory agents; immunosuppressive agents; immune modulators; colchicine; COVID-19; SARS-CoV-2; CORONAVIRUS; PROTEIN; ACE2;
D O I
10.2174/1381612827666211210142352
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The current coronavirus disease (COVID-19) pandemic has affected millions of individuals worldwide. Despite extensive research efforts, few therapeutic options currently offer direct clinical benefits for COVID-19 patients. Despite the advances in our understanding of COVID-19, the mortality rates remain significantly high owing to the high viral transmission rates in several countries and the rise of various mutations in the SARS-CoV-2. One currently available and widely used drug that combines both anti-inflammatory and immunomodulatory actions is colchicine, which has been proposed as a possible treatment option for COVID-19. Colchicine still did not get much attention from the medical and scientific communities despite its anti-inflammatory and immunomodulatory mechanisms of action and positive preliminary data from early trials. This literature review article provides the scientific rationale for repurposing colchicine as a potential therapy for COVID-19. Further, we summarize colchicine's mechanisms of action and possible roles in COVID-19 patients. Finally, we supplement this review with a summary of the doses, side effects, and early efficacy data from clinical trials to date. Despite the promising early findings from multiple observational and clinical trials about the potential of colchicine in COVID-19, the data from the RECOVERY trial, the largest COVID-19 randomized controlled trial (RCT) in the world, showed no evidence of clinical benefits in mortality, hospital stays, or disease progression (n = 11340 patients). However, multiple other smaller clinical trials showed significant clinical benefits. We conclude that while current evidence does not support the use of colchicine for treating COVID-19, the present body of evidence is heterogeneous and inconclusive. The drug cannot be used in clinical practice or abandoned from clinical research without additional large RCTs providing more robust evidence. At present, the drug should not be used except for investigational purposes.
引用
收藏
页码:3194 / 3201
页数:8
相关论文
共 50 条
  • [21] Telemedicine in the COVID-19 Era: A Narrative Review Based on Current Evidence
    Nittari, Giulio
    Savva, Demetris
    Tomassoni, Daniele
    Tayebati, Seyed Khosrow
    Amenta, Francesco
    INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH, 2022, 19 (09)
  • [22] Postmortem findings in COVID-19 fatalities: A systematic review of current evidence
    Menezes, Ritesh G.
    Rizwan, Tehlil
    Ali, Syed Saad
    Hassan, Wardah
    Khetpal, Akash
    Aqil, Mohammad
    Madadin, Mohammed
    Siddiqi, Tariq Jamal
    Usman, Muhammad Shariq
    LEGAL MEDICINE, 2022, 54
  • [23] Antiviral Therapy inManagement of COVID-19: a Systematic Review on Current Evidence
    Yousefifard, Mahmoud
    Zali, Alireza
    Ali, Kosar Mohamed
    Neishaboori, Arian Madani
    Zarghi, Afshin
    Hosseini, Mostafa
    Safari, Saeed
    ARCHIVES OF ACADEMIC EMERGENCY MEDICINE, 2020, 8 (01)
  • [24] The effect of tocilizumab on severe COVID-19 infection: Review of current evidence
    Yakar, Halil Ibrahim
    Pazarli, Ahmet Cemal
    Inonu Koseoglu, Handan
    Kanbay, Asiye
    TUBERKULOZ VE TORAKS-TUBERCULOSIS AND THORAX, 2021, 69 (01): : 74 - 83
  • [25] Psychological Symptoms of COVID-19 Epidemic: A Systematic Review of Current Evidence
    SeyedAlinaghi, SeyedAhmad
    Karimi, Amirali
    Shobciri, Parisian
    Nowroozi, Ali
    Mehraeen, Esmaeil
    Afsahi, Amir Masoud
    Barzegary, Alireza
    PSIHOLOGIJA, 2021, 54 (02) : 173 - 192
  • [26] PROBIOTICS IN PREVENTION AND TREATMENT OF COVID-19: A SYSTEMATIC REVIEW OF CURRENT EVIDENCE
    Alinaghi, S. Seyed
    Shahidi, R.
    Afzalian, A.
    Paranjkhoo, P.
    Ghorbanzadeh, K.
    Mojdeganlou, H.
    Razi, A.
    Mojdeganlou, P.
    Dashti, M.
    Ghasemzadeh, A.
    Parikhani, S. N.
    Pashaei, A.
    Karimi, A.
    Ahmadi, S.
    Mehraeen, E.
    Hackett, D.
    INFEKTSIYA I IMMUNITET, 2023, 13 (04): : 709 - 722
  • [27] Colchicine as a Potential Treatment Choice for COVID-19 Patients in Developing Countries: COVID-19 and Colchicine
    Ghang, Byeongzu
    Kim, Jinseok
    JOURNAL OF RHEUMATIC DISEASES, 2022, 29 (01): : 56 - 57
  • [28] Impact of colchicine on mortality and morbidity in COVID-19: a systematic review
    Sanghavi, Devang
    Bansal, Pankaj
    Kaur, Ikwinder Preet
    Mughal, Mohsin Sheraz
    Keshavamurthy, Chandana
    Cusick, Austin
    Schram, Jennifer
    Yarrarapu, Siva Naga S.
    Giri, Abhishek R.
    Kaur, Nirmaljot
    Franco, Pablo Moreno
    Abril, Andy
    Aslam, Fawad
    ANNALS OF MEDICINE, 2022, 54 (01) : 775 - 789
  • [29] A Review of the Evidence for Corticosteroids in COVID-19
    Johns, Meagan
    George, Stephy
    Taburyanskaya, Margarita
    Poon, Yi Kee
    JOURNAL OF PHARMACY PRACTICE, 2022, 35 (04) : 626 - 637
  • [30] Liver injury in COVID-19: The current evidence
    Alqahtani, Saleh A.
    Schattenberg, Joern M.
    UNITED EUROPEAN GASTROENTEROLOGY JOURNAL, 2020, 8 (05) : 509 - 519